Structure-based de novo design of Eya2 phosphatase inhibitors

Journal of Molecular Graphics and Modelling

Volumn 38, Issue , 2012, Pages 382-388

  Park, Hwangseo ^a   Ryu, Seong Eon ^b   Kim, Seung Jun ^c  

^a Sejong University   (South Korea)

^b Hanyang University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Anticancer agents; Chelating group; De novo design; Eya2 phosphatase; Inhibitor

Indexed keywords

ACTIVE SITE; ANTI-CANCER AGENTS; CHELATING GROUPS; DE NOVO DESIGN; DRUG CANDIDATES; EXPERIMENTAL EVIDENCE; HUMAN CANCER; INHIBITOR; INHIBITORY ACTIVITY; PHOSPHATASE INHIBITORS; PHYSICOCHEMICAL PROPERTY; PROTEIN-TYROSINE PHOSPHATASE; SMALL-MOLECULE INHIBITORS; STRUCTURAL FEATURE; STRUCTURE-BASED;

AMINO ACIDS; CHELATION;

PHOSPHATASES;

CHELATING AGENT; EYES ABSENT HOMOLOGUE 2 PROTEIN; EYES ABSENT HOMOLOGUE 2 PROTEIN INHIBITOR; MAGNESIUM; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHELATION; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CHELATING AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAGNESIUM; MODELS, MOLECULAR; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867458442     PISSN: 10933263     EISSN: 18734243     Source Type: Journal    
DOI: 10.1016/j.jmgm.2012.05.003     Document Type: Article

References (17)

1. J.P. Rayapureddi, C. Kattamuri, B.D. Steinmetz, B.J. Frankfort, E.J. Ostrin, G. Mardon, and R.S. Hegde Eyes absent represents a class of protein tyrosine phosphatases Nature 426 2003 295 298
2. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, A. Osterman, A. Godzik, T. Hunter, J. Dixon, and T. Mustelin Protein tyrosine phosphatases in the human genome Cell 117 2004 699 711
3. L. Zhang, N. Yang, J. Huang, R.J. Buckanovich, S. Liang, A. Barchetti, C. Vezzani, A. O'Brien-Jenkins, J. Wang, M.R. Ward, M.C. Courreges, S. Fracchioli, A. Medina, D. Katsaros, B.L. Weber, and G. Coukos Transcriptional coactivator Drosophilia eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth Cancer Research 65 2005 925 932
4. J. Guo, C. Liang, L. Ding, N. Zhou, and Q. Ye Drosophila eyes absent homologue 2 is up-regulated in lung adenocarcinoma Chinese-German Journal of Clinical Oncology 8 2009 681 684
5. S.J. Miller, Z.D. Lan, A. Hardiman, J. Wu, J.J. Kordich, D.M. Patmore, R.S. Hegde, T.P. Cripe, J.A. Cancelas, M.H. Collins, and N. Ratner Inhibition of eyes absent homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis Oncogene 29 2010 368 379
6. R.N. Pandey, R. Rani, E.-J. Yeo, M. Spencer, S. Hu, R.A. Lang, and R.S. Hegde The eyes absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells Oncogene 29 2010 3715 3722
7. S.-K. Jung, D.G. Jeong, S.J. Chung, J.H. Kim, B.C. Park, N.K. Tonks, S.E. Ryu, and S.J. Kim Crystal structure of ED-Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor FASEB Journal 24 2010 560 569
8. N. Krishnan, D.G. Jeong, S.-K. Jung, S.E. Ryu, A. Xiao, C.D. Allis, S.J. Kim, and N.K. Tonks Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent Journal of Biological Chemistry 284 2009 16066 16070
9. H. Park, S.-K. Jung, K.R. Yu, J.H. Kim, Y.-S. Kim, J.H. Ko, B.C. Park, and S.J. Kim Structure-based virtual screening approach to the discovery of novel inhibitors of eyes absent 2 phosphatase with various metal chelating moieties Chemical Biology and Drug Design 78 2011 642 650
10. H. Park, J.-Y. Jeon, S.Y. Kim, D.G. Jeong, and S.E. Ryu Identification of novel inhibitors of mitogen-activated protein kinase phosphatase-1 with structure-based virtual screening Journal of Computer-Aided Molecular Design 25 2011 469 475
11. R. Wang, Y. Gao, L. Lai, and LigBuilder. A multi-purpose program for structure-based drug design Journal of Molecular Modeling 6 2000 498 516
12. R. Wang, L. Liu, L. Lai, and Y. Tang SCORE: a new empirical method for estimating the binding affinity of a protein-ligand complex Journal of Molecular Modeling 4 1998 379 394
13. J. Gasteiger, and M. Marsili Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges Tetrahedron 36 1980 3219 3228
14. H. Kang, H. Choi, and H. Park Prediction of molecular solvation free energy based on the optimization of atomic solvation parameters with genetic algorithm Journal of Chemical Information and Modeling 47 2007 509 514
15. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function Journal of Computational Chemistry 19 1998 1639 1662
16. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, and Experimental computational approaches to estimate solubility and permeability in drug discovery and development settings Advanced Drug Delivery Reviews 23 1997 3 20
17. B.K. Shoichet, A.R. Leach, and I.D. Kuntz Ligand solvation in molecular docking Proteins 34 1999 4 16